Is serum PSA a predictor of male hypogonadism? Testing the hypothesis

Amadi, Collins; Green, Kinikanwo I.; Odum, Ehimen P.

doi:10.20945/2359-3997000000326

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the exact relationship between testosterone and PC is unclear, the production of PSA is under testosterone influence and untreated patients with hypogonadism have generally lower PSA compared to eugonadal men [ 130 ]. Furthermore, a low PSA has been suggested as a marker for hypogonadism [ 131 , 132 ]. Consequently, when using PSA as a screening tool for PC in untreated hypogonadal men, the PSA cut off value for further investigations should probably be held at a lower level since the number of detected PC was high in a group hypogonadal men with PSA below 4 ng/ml [ 133 ].…”

Section: Screening Of Prostate Cancermentioning

confidence: 99%

Androgens, aging, and prostate health

Welén

Damber

2022

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Due to late onset hypogonadism (LOH), there is an increased usage of testosterone replacement therapy (TRT) in the aging male population. Since prostate is a target organ for androgens and anti-androgenic strategies are used to treat and palliate benign prostate hyperplasia (BPH) and prostate cancer (PC), the prevalence of both increases with age, the possible influence of TRT on prostate health becomes highly relevant. The present review summarizes existing data on the associations between endogenous hormone concentrations and prostate growth and concludes that circulating concentrations of androgens do not appear to be associated with the risks of development of BPH or initiation or progression of PC. The explanation for these findings relates to an apparent insensitivity of prostatic tissue to changes of testosterone concentrations within the physiological range.

show abstract